Alterations in striatal NMDA receptor subunits associated with the development of dyskinesia in the MPTP-lesioned macaque model of Parkinson's disease

被引：0
|
作者：
Hallett, PJ
Dunah, AW
Crossman, AR
Brotchie, JM
Standaert, DG
机构：
来源：
MOVEMENT DISORDERS | 2004年 / 19卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P531
引用
收藏
页码：S189 / S190
页数：2
相关论文
共 50 条
  • [21] The Selective Mu-Opioid Receptor Antagonist ADL5510 Reduces Levodopa-Induced Dyskinesia Without Affecting Antiparkinsonian Action in MPTP-Lesioned Macaque Model of Parkinson's Disease
    Koprich, James B.
    Fox, Susan H.
    Johnston, Tom H.
    Goodman, Allan
    Le Bourdonnec, Bertrand
    Dolle, Roland E.
    DeHaven, Robert N.
    DeHaven-Hudkins, Diane L.
    Little, Patrick J.
    Brotchie, Jonathan M.
    MOVEMENT DISORDERS, 2011, 26 (07) : 1225 - 1233
  • [22] Synaptic Recruitment of AMPA Glutamate Receptor Subunits in Levodopa-Induced Dyskinesia in the MPTP-Lesioned Nonhuman Primate
    Silverdale, Monty A.
    Kobylecki, Christopher
    Hallett, Penelope J.
    Li, Qin
    Dunah, Anthone W.
    Ravenscroft, Paula
    Bezard, Erwan
    Brotchie, Jonathan M.
    SYNAPSE, 2010, 64 (02) : 177 - 180
  • [23] Fipamezole (JP-1730) is a potent α2 adrenergic receptor antagonist that reduces levodopa-induced dyskinesia in the MPTP-lesioned primate model of Parkinson's disease
    Savola, JM
    Hill, M
    Engstrom, M
    Merivuori, H
    Wurster, S
    McGuire, SG
    Fox, SH
    Crossman, AR
    Brotchie, JM
    MOVEMENT DISORDERS, 2003, 18 (08) : 872 - 883
  • [24] The histamine H2 receptor antagonist, famotidine, reduces L-dopa-induced motor complications in the MPTP-lesioned macaque model of Parkinson's disease
    Fox, S. H.
    Johnston, T. H.
    Vandermeij, A.
    Brotchie, J. M.
    MOVEMENT DISORDERS, 2009, 24 : S351 - S352
  • [25] Dynamic alterations of gene expression of nicotinic acetylcholine receptor α7, α4 and β2 subunits in an acute MPTP-lesioned mouse model
    Hu, Jun
    Zhu, Chenlei
    Liu, Yuan
    Wang, Fang
    Huang, Zuhu
    Fan, Weimin
    Wu, Jie
    NEUROSCIENCE LETTERS, 2011, 494 (03) : 232 - 236
  • [26] Docosahexaenoic acid provides protective mechanism in bilaterally MPTP-lesioned rat model of Parkinson's disease
    Hacioglu, Gulay
    Seval-Celik, Yasemin
    Tanriover, Gamze
    Ozsoy, Ozlem
    Saka-Topcuoglu, Esen
    Balkan, Sevin
    Agar, Aysel
    FOLIA HISTOCHEMICA ET CYTOBIOLOGICA, 2012, 50 (02) : 228 - 238
  • [27] CXCR4 knockout induces neuropathological changes in the MPTP-lesioned model of Parkinson's disease
    Ma, Jianjun
    Dong, Linrui
    Chang, Qingqing
    Chen, Siyuan
    Zheng, Jinhua
    Li, Dongsheng
    Wu, Shaopu
    Yang, Hongqi
    Li, Xue
    BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE, 2023, 1869 (02):
  • [28] PYM50028 restores dopamine transporter (DAT) levels in striatal dopamine terminals in a MPTP-lesioned mouse model of Parkinson's disease
    Visanji, N. P.
    Johnston, T. H.
    Brotchie, J. M.
    Hatton, S. L.
    Callizot, N.
    Orsi, A.
    Rees, D.
    MOVEMENT DISORDERS, 2006, 21 : S643 - S643
  • [29] Pharmacological characterization of psychosis-like behavior in the MPTP-lesioned nonhuman primate model of Parkinson's disease
    Visanji, Naomi P.
    Gomez-Ramirez, Jordi
    Johnston, Tom H.
    Pires, Donna
    Voon, Valerie
    Brotchie, Jonathan M.
    Fox, Susan H.
    MOVEMENT DISORDERS, 2006, 21 (11) : 1879 - 1891
  • [30] FP0011 extends the duration of the anti-parkinsonian actions of L-DOPA and reduces L-DOPA-induced dyskinesia in the MPTP-lesioned macaque model of Parkinson's disease
    Brotchie, J. M.
    Johnston, T. H.
    Fox, S. H.
    Zerr, P.
    Tiberghien, F.
    Bossi, L.
    MOVEMENT DISORDERS, 2007, 22 : S95 - S95
12345